Form 4: Athira Pharma GC Granted Performance-Based Stock Options

Athira Pharma's General Counsel and CCO, Mark Worthington, was granted options to purchase 34,358 shares of common stock with an exercise price of $4.07, vesting based on performance and service.

Summary

• Mark Worthington, General Counsel and Chief Compliance Officer (CCO) of Athira Pharma, Inc. (ATHA), was granted an option to purchase 34,358 shares of common stock.
• The option's exercise price is $4.07 per share, which was the closing price on the Nasdaq Global Market on the grant date.
• The grant date for the option was September 24, 2025.
• Vesting of the option is contingent upon two requirements: a Milestone Requirement and a Service-Based Requirement.
• The Milestone Requirement was satisfied on December 23, 2025.
• The Service-Based Requirement dictates that 50% of the shares will vest on December 23, 2026, and 1/36th of the remaining 50% will vest on the 23rd day of each month thereafter, subject to continued service.
• The option is scheduled to expire on September 23, 2035.
• Following this transaction, Mark Worthington beneficially owns 34,358 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a routine disclosure, the grant of performance and service-based options to a key executive is a positive signal for management alignment and retention, without indicating any immediate negative implications for the company's financial health or operations.

Positives

• The grant of stock options aligns the interests of the General Counsel and CCO, Mark Worthington, with those of the shareholders, incentivizing long-term company performance.
• The performance-based vesting (Milestone Requirement) ensures that a specific company objective was met before the options could begin to vest based on service.

Future Outlook

The vesting schedule for the stock option extends through December 23, 2026, and monthly thereafter, indicating an expectation of continued service from Mark Worthington and a long-term incentive structure tied to company performance and executive retention.

Industry Context

The grant of performance and service-based stock options to key executives like the General Counsel and CCO is a standard practice in the biotechnology and pharmaceutical industry. It serves as a common mechanism for executive compensation, aiming to attract, retain, and motivate talent by aligning their financial interests with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• Stock option grants with performance and service-based vesting are a widely adopted compensation tool across the biotech sector, similar to practices at companies like Biogen, Amgen, or Gilead Sciences, which frequently use equity incentives to align executive and shareholder interests.
• The exercise price being set at the closing market price on the grant date is a standard practice for incentive stock options, ensuring that the executive benefits only if the company's stock price appreciates from that point.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options, but also benefit from increased executive alignment and motivation to enhance long-term shareholder value.
• Employees: Standard executive compensation practices can set a precedent or benchmark for other employee incentive programs.

Next Steps

• Continued service by Mark Worthington to meet the service-based vesting requirements.
• Future vesting events for the remaining 50% of the option shares on December 23, 2026, and monthly thereafter.

Key Dates

Recommendation

A routine Form 4 filing detailing an executive's stock option grant does not typically provide sufficient new information to alter an investment recommendation. It primarily serves to disclose insider holdings and compensation structure, which is generally expected and does not fundamentally change the investment thesis for Athira Pharma.

Keywords

Athira Pharma, ATHA, Stock Option, Insider Transaction, Form 4, Mark Worthington, General Counsel, CCO, Equity Incentive Plan, Executive Compensation